SIFROL TABLET 0.125 MG

BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (GERMANY)🇸🇬 Health Sciences Authority

Approval Date: Jan 4, 2000
Approval ID: b3378cb86d475376
Company: BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (GERMANY)
Type: Therapeutic

Approval Details

Approval Id: b3378cb86d475376
Drug Name: SIFROL TABLET 0.125 MG
Product Name: SIFROL TABLET 0.125 MG
Approval Number: SIN11253P
Approval Date: 2000-01-04
Registrant: BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Licence Holder: BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET
Dosage: 4.2 Posology and method of administration (all dose information refers to pramipexole salt form) Parkinson’s disease Dosage Initial treatment: As shown below dosages should be increased gradually from a starting dose of 0.375 mg per day and then increased every 5 – 7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect. <img src="/TGIF/Sifrol-Table1.png" alt="Sifrol Dosage Table 1" /> If a further dose increase is necessary the daily dose should be increased by 0.75 mg at weekly intervals up to a maximum dose of 4.5 mg per day. Patients already taking SIFROL tablets may be switched to SIFROL extended-release tablets overnight, at the same daily dose. Dosage adjustment may be necessary for some patients according to response. Maintenance treatment: The individual dose should be in the range of 0.375 mg to a maximum of 4.5 mg per day. During dose escalation in pivotal studies both in early and advanced disease efficacy was observed starting at a daily dose of 1.5 mg. This does not preclude that in individual patients doses higher than 1.5 mg per day can result in additional therapeutic benefit. This applies particularly to patients with advanced disease where a reduction of the levodopa therapy is intended. Treatment discontinuation: SIFROL tablets and extended-release tablets should be tapered off at a rate of 0.75 mg per day until the daily dose has been reduced to 0.75 mg. Thereafter the dose should be reduced by 0.375 mg per day. (see section Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) Missed dose When the intake of a dose is missed, SIFROL prolonged-release tablets should be taken up to 12 hours after the regularly scheduled time. After 12 hours, the missed dose should be left out and the next dose should be taken on the following day at the next regularly scheduled time. Dosing in patients with concomitant levodopa therapy: In patients with concomitant levodopa therapy it is recommended that the dosage of levodopa is reduced during both dose escalation and maintenance treatment with SIFROL. This may be necessary in order to avoid excessive dopaminergic stimulation. Dosing in patients with renal impairment: The elimination of Pramipexole is dependent on renal function. The following dosage schedule is suggested for initiation of therapy: Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose or dosing frequency. Tablets In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of SIFROL tablets should be administered in two divided doses, starting at 0.125 mg twice a day (0.25 mg daily). A maximum daily dose of 2.25 mg pramipexole should not be exceeded. In patients with a creatinine clearance less than 20 ml/min, the daily dose of SIFROL tablets should be administered in a single dose, starting at 0.125 mg daily. A maximum daily dose of 1.5 mg pramipexole should not be exceeded. If renal function declines during maintenance therapy reduce SIFROL daily dose by same percentage as decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then reduce SIFROL daily dose by 30%. The daily dose can be administered in two divided doses if creatinine clearance is between 20 and 50 ml/min and as a single daily dose if creatinine clearance is less than 20 ml/min. Extended-release tablets In patients with a creatinine clearance between 30 and 50 ml/min, treatment should be started with 0.375 mg SIFROL extended-release tablets every other day. Caution should be exercised and careful assessment of therapeutic response and tolerability should be made before increasing to daily dosing after one week. If a further dose increase is necessary, daily doses should be increased by 0.375 mg pramipexole at weekly intervals up to a maximum dose of 2.25 mg pramipexole per day. No data are available for the treatment of patients with a creatinine clearance below 30 ml/min with SIFROL extended-release tablets. The use of SIFROL tablets should be considered. If renal function declines during maintenance therapy the recommendations given above should be followed. Dosing in patients with hepatic impairment: Dose reduction is not considered necessary in patients with hepatic impairment. Method of Administration Tablets The tablets should be taken orally, swallowed with water, and can be taken either with or without food. The daily dosage is administered in equally divided doses 3x per day. Prolonged-release tablets The prolonged-release tablets should be taken once daily at about the same time each day. The prolonged-release tablets should be swallowed whole with water, and must not be chewed, divided or crushed. The prolonged-release tablets may be taken with or without food. Restless Legs Syndrome Dosage The recommended starting dose of SIFROL is 0.125 mg taken once daily 2 – 3 hours before bedtime. For patients requiring additional symptomatic relief, the dose may be increased every 4 – 7 days to a maximum of 0.75 mg per day (as shown in the table below). <img src="/TGIF/Sifrol-Table2.png" alt="Sifrol Dosage Table 2" /> Treatment discontinuation: Since daily dose for the treatment of Restless Legs Syndrome will not exceed 0.54 mg of base (0.75 mg of salt). SIFROL can be discontinued without tapering off. Rebound (worsening of symptoms after abrupt discontinuation of treatment) cannot be excluded. In a 26 week placebo controlled clinical trial, rebound of RLS symptoms (worsening of symptom severity as compared to baseline) was observed in 10% of patients (14 out of 135) after abrupt discontinuation of pramipexole. This effect was found to be similar across all doses. Dosing in patients with renal impairment: The elimination of SIFROL is dependent on renal function and closely related to the creatinine clearance. Based on a pharmacokinetic study in renally impaired subjects, patients with a creatinine clearance above 20 ml/min require no reduction in daily dose. The use of SIFROL in RLS patients with renal impairment has not been studied. Dosing in patients with hepatic impairment: Dose reduction is not considered necessary in patients with hepatic impairment, as approx. 90% of absorbed drug is excreted through the kidneys. Dosing in children and adolescents: Safety and efficacy of SIFROL have not been established in children and adolescents up to 18 years. Method of Administration The tablets should be taken orally, swallowed with water, and can be taken either with or without food.
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic Indications Tablets SIFROL tablet is indicated in the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa. SIFROL tablet is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome. Extended-release tablets SIFROL extended-release tablet is indicated in the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.
Contraindications: 4.3 Contraindications Hypersensitivity to pramipexole or any other component of the product.
Atc Code: N04BC05
Atc Item Name: pramipexole
Pharma Manufacturer Name: BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.

Active Ingredients

PRAMIPEXOLE 2HCl MONOHYDRATE EQV PRAMIPEXOLE

0.125mg

PRAMIPEXOLE 2HCL MONOHYDRATE EQV PRAMIPEXOLE

0.125 MG

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 4, 2000

Approval ID

b3378cb86d475376

Type

Therapeutic

Back to HSA Approvals